文献速递糖尿病性腺与生殖内分泌肥胖与代谢综合征

女性2型糖尿病合并心血管疾病的性别特异性心血管危险因素与治疗:进展与知识空白

Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

本文综述女性2型糖尿病合并心血管疾病的性别特异性危险因素及临床试验中性别相关局限。女性特有危险因素包括早初潮、早绝经、多囊卵巢综合征、妊娠及不良妊娠结局、乳腺癌史和自身免疫病。新型降糖与心血管药物试验中女性入组不足且男女参与者临床特征差异显著,导致疗效与副作用性别差异的证据缺乏。

要点

  • 女性特有心血管危险因素包括早初潮、早绝经、不规则周期、多囊卵巢综合征。
  • 妊娠、不良妊娠结局、乳腺癌史和自身免疫病也是女性特有危险因素。
  • 新型糖尿病与心血管药物试验女性入组不足,男女参与者临床特征差异显著。

核心结论

  • 为改善女性糖尿病患者健康,筛查和治疗决策应考虑性别特异性心血管危险因素。
  • 心血管和糖尿病药物研究必须确保性别充分代表性,并按性别报告参与者特征和结局。

研究设计与样本

  • 本文为综述,采用Ovid Medline(R) All进行两次文献检索。
  • 第一次检索关于心血管疾病风险、治疗与糖尿病的性别差异文献,第二次聚焦GLP-1/SGLT-2/DPP-4药物性别差异的随机对照试验数据。

主要发现

  • 女性特有心血管危险因素包括早初潮、早绝经或不规则周期、多囊卵巢综合征、妊娠及不良妊娠结局、乳腺癌史和自身免疫病。
  • 新型糖尿病和心血管药物临床试验中女性人群入组不足,男女参与者临床特征存在显著差异。
  • 因此评估治疗疗效和副作用潜在性别差异的证据一直缺乏。

临床怎么用

  • 作者认为,筛查和治疗决策应考虑性别特异性心血管危险因素以改善女性糖尿病患者健康。
  • 作者认为,心血管和糖尿病药物研究必须确保性别充分代表性并按性别报告参与者特征和结局。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are large disparities in the impact of diabetes on cardiovascular disease (CVD) risk and outcomes by sex and gender. Achieving health equity requires understanding risks and medication efficacy in female patients, especially now, as novel pharmacologic treatments are transforming the diabetes and CVD treatment landscape. This review examines 2 bodies of research that can inform sex differences in CVD in patients with diabetes: female-specific risk factors for CVD and sex-related limitations of clinical trial research in evaluating novel diabetes and CVD treatments. METHODS: Two literature searches were performed using Ovid Medline(R) All. The first retrieved manuscripts covering sex and gender differences related to CVD risk and therapies and diabetes. The second focused on randomized controlled trial data on sex/gender differences and GLP-1/SGLT-2/DPP-4 drugs. RESULTS: Female-specific risk factors for CVD include early menarche, premature or early menopause, irregular cycles and polycystic ovary syndrome; pregnancy; adverse pregnancy outcomes; history of breast cancer; and autoimmune diseases. Clinical trials of novel pharmacological treatments for diabetes and CVD have undersampled female populations, and clinical characteristics of male and female participants have differed significantly. Thus, evidence to evaluate potential sex differences in treatment efficacy and side effects has been lacking. CONCLUSION: To improve health of female patients with diabetes, sex-specific cardiovascular risk factors should be taken into account in screening and treatment decisions. Further, studies of cardiovascular and diabetes medications must ensure adequate representation by sex and report participant characteristics and outcomes by sex.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. LeBlanc ES, Brooks N, Davies M, et al. Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps. J Clin Endocrinol Metab. 2024. PMID: 39312230. doi:10.1210/clinem/dgae655

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。